Genome-wide association studies of binge-eating behaviour and anorexia nervosa yield insights into the unique and shared biology of eating disorder phenotypes

Jet D Termorshuizen [1,*], Helena L Davies [2,3,4,5,*], Sang-Hyuck Lee [4,5,*], Laura M Huckins [6,†], Cynthia M Bulik [1,7,8,†]; Gerome Breen [4,5,†], Jonathan RI Coleman [4,5,†], for the Eating Disorder Working Group of the Psychiatric Genomics Consortium

[1] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden

[2] Center for Eating and Feeding Disorders Research, Mental Health Center Ballerup, Copenhagen University Hospital – Mental Health Services CPH, Denmark

[3] Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Mental Health Services Copenhagen, Roskilde, Denmark

[4] Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom

[5] National Institute for Health and Care Research Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, United Kingdom

[6] Department of Psychiatry, Yale University, United States of America

[7] Department of Psychiatry, University of North Carolina at Chapel Hill, United States of America

[8] Department of Nutrition, University of North Carolina at Chapel Hill, United States of America

[*] Share first authorship

[†] Share senior authorship

ABSTRACT

Eating disorders (EDs)—including anorexia nervosa (AN), bulimia nervosa, and binge-eating disorder—are clinically distinct, but exhibit high symptom overlap and comorbidity. Genomic analyses to date have only examined AN. We conducted the first genome-wide association meta-analysis of binge-eating behaviour (BE; 39,279 cases, 1,227,436 controls, all from European genetic ancestries), alongside new analyses of AN (24,223 cases, 1,243,971 controls, all from European genetic ancestries) and its subtypes. We implicated six genomic loci associated with BE, including known associations with higher body mass index (BMI) and impulse-control behaviours. BE and AN exhibit genetic similarity, including positive genetic correlation with psychiatric disorders, and genetic dissimilarity, including opposing genetic correlations with anthropometric traits. Genomic structural equation modelling analyses indicate that most genetic signal in EDs is independent of BMI. We have extended ED genomics beyond AN; work is underway to diversify further, incorporating multiple diagnoses and global genetic ancestries.

Eating disorders—including anorexia nervosa (AN), bulimia nervosa, and binge-eating disorder, among others—represent a suite of clinical presentations that are distinct in their pure forms, yet show considerable overlap in symptoms, as reflected in diagnostic migration over time [1–3]. AN—marked by low weight, fear of weight gain, and an inability to recognize the seriousness of the low weight—has two subtypes: the restricting subtype (AN-R), in which low weight is achieved by caloric restriction and increased energy expenditure, and the binge-eating/purging subtype (AN-BP), in which restriction is coupled with binge eating (BE) and/or compensatory purging behaviours. Bulimia nervosa occurs in individuals at normal or high weight and is characterised by the combination of BE and compensatory behaviours (e.g., fasting, self-induced vomiting, laxative use, diuretic use). Binge-eating disorder mirrors the BE component of bulimia nervosa and also occurs at both normal and high weights, but in the absence of regular compensatory behaviours [1].

To date, genome-wide association studies (GWASs) of eating disorders have focused primarily on AN [4–7] in part due to its elevated mortality [8]. The most recent AN GWAS [7] included 16,992 cases and identified eight genome-wide significant loci. Genetic correlation analyses showed high correlations with other psychiatric disorders, and suggested that metabolic and anthropometric factors might also underlie AN pathophysiology [5,7]. The metabolic aspect of AN is reflected by a positive genetic correlation with high-density lipoprotein cholesterol and negative genetic correlations with insulin resistance, leptin, and type 2 diabetes. Importantly, these genetic correlations were independent of body mass index (BMI)—a significant finding given that a low BMI is a defining feature of AN.

To fully understand the genetic landscape of eating disorders, it is essential to advance eating disorder genetics beyond the study of AN. Substantial genetic correlation between AN and bulimia nervosa has been shown in family and twin studies [9,10], suggesting that these phenotypes may share genetic risk. This may partially reflect the presence of BE as a transdiagnostic symptom, common both to bulimia nervosa and to AN-BP. Here, we

present the first GWAS meta-analysis of BE. We additionally conducted an AN GWAS meta-analysis with augmented sample size and increased statistical power, which also afforded the first GWAS of explicitly defined AN subtypes (restricting and binge-eating/purging). We then assessed genetic commonalities and differences between the eating disorder phenotypes.

RESULTS

Summary of phenotypes

We operationalized five phenotypes (**Table 1**) to advance progress for eating disorder GWASs: narrowly-defined (BE-NARROW) and broadly-defined BE (BE-BROAD), and AN and its two subtypes (AN-R and AN-BP). We primarily report results for AN and BE-BROAD, which captures the common genetic component of BE with greater statistical power than BE-NARROW (Methods). Results for BE-NARROW, AN-R and AN-BP are reported in the Supplementary Results.

Table 1 approximately here

Association meta-analyses

Our BE-BROAD GWAS included 17 European-ancestry datasets with 39,279 cases and 1,227,436 controls, assessing 6,244,919 common (minor allele frequency ≥ 1%), high-confidence (imputation INFO score > 0.6), autosomal single nucleotide polymorphisms (SNPs; Supplementary Table 1). Conditional and joint analyses confirmed six independently-associated loci (Figure 1; Table 2; Supplementary Figures 1-6; Supplementary Table 2). The liability-scale SNP-based heritability for BE-BROAD was 5% (SE 0.4%, assuming population prevalence of 4.5% [11]), with an intercept of 1.03, significantly >1 (Supplementary Table 3). While this can indicate confounding, it is also typical to observe in large GWAS of highly polygenic phenotypes [12].

For AN, we identified eight independently-associated genomic loci in 26 European-ancestry datasets with 24,223 cases and 1,243,971 controls, across 6,926,820 common, high-confidence, autosomal SNPs (Figure 1; Table 2; Supplementary Figures 7-14; Supplementary Tables 1 and 2). Six of these loci were detected in a previous AN GWAS[20] and two were newly identified. Three previously significant loci (on chromosome 2 and 3 from Watson et al [7], and on chromosome 12 from Duncan et al [5]) did not reach genome-wide significance ($P = 2x10^{-7}$ - $6x10^{-7}$). The liability-scale SNP-based heritability was 13% (SE 0.7%, assuming population prevalence of 1.5% [13]), with an intercept of 1.02, significantly >1 (Supplementary Table 3).

We additionally conducted analyses on chromosome X for a subset of studies with available data (Supplementary Table 4). No genome-wide significant loci were identified for BE-BROAD nor for AN, although one genome-wide significant locus was identified for BE-NARROW (Supplementary Results, Supplementary Figure 15, Supplementary Table 5).

Given known sex differences in eating disorders, and mostly female cases in our data (94% in AN, 96% in BE-BROAD), we carried out female-only GWASs as sensitivity analyses. Results were similar to the main analyses, with differences attributable to the reduction in sample size (Supplementary Results, Supplementary Table 6).

Figure 1 approximately here

Table 2 approximately here

Genetic relationship between BE, AN, and other traits

We assessed the genetic similarity of BE-BROAD and AN through examining their SNP-r_g, as well as their SNP-r_g with other traits, and via case-case GWAS [14]. The SNP-r_g between BE-BROAD and AN was 0.46 (SE 0.04, $P = 3.44$ x 10^{-30}), indicating moderate genetic overlap (Supplementary Table 7). Case-case GWAS leverages a genetic distance measure representing "the average squared difference in allele frequency at causal SNPs"

[14]. The genetic distance between individuals with AN and controls was highest (0.46) and similar to that between both case groups (0.40), whereas the genetic distance between individuals with BE-BROAD and controls was smaller (0.25, Figure 2). We identified case-divergent loci on chromosomes 1, 3, and 5—all overlapping with independent loci identified in the AN GWAS (Figure 1), suggesting that some loci differentiating AN from controls also differentiate AN from BE-BROAD.

Figure 2 approximately here

We subsequently used LDSC to calculate pairwise SNP-r_g for both BE-BROAD and AN with 225 traits including psychiatric, personality, metabolic, and anthropometric traits (Table 3, Supplementary Table 8). We generally observed positive SNP-r_g of BE-BROAD with psychiatric traits and disorders, and with anthropometric traits, except for negative SNP-r_g with persistent thinness and pubertal growth. In contrast, significant SNP-r_g with metabolic traits were absent for BE-BROAD except for BMI-adjusted fasting insulin. We validate previously observed SNP-r_g patterns with AN [7], with some updates (Table 3, Supplementary Table 8). We found positive SNP-r_g across psychiatric disorders, as well as with neuroticism, educational attainment, and physical activity. We observed negative SNP-r_g across anthropometric traits, and notably, a non-significant SNP-r_g with persistent thinness. Metabolic SNP-r_g mirror Watson et al., with predominantly negative SNP-r_g, except for total cholesterol in high-density lipoprotein [7].

Next, we determined if there were significant differences between the SNP-r_g of BE-BROAD and SNP-r_g of AN with other traits using LDSC jackknife (Figure 3, Supplementary Figure 16, Supplementary Table 9). Whilst the majority of psychiatric and behavioural traits and disorders showed similar SNP-r_g with BE-BROAD and AN, ADHD showed significantly greater SNP-r_g ($P = 1.06 \times 10^{-7}$) with BE-BROAD than with AN, and obsessive-compulsive disorder showed significantly greater SNP-r_g ($P = 4.79 \times 10^{-5}$) with AN than with BE-BROAD.

We found further significant differences for the alcohol use disorder identification test problem items, four smoking-related phenotypes, and general risk tolerance, with which BE-BROAD was significantly positively correlated but AN was not. Automobile speeding propensity also showed significantly different SNP-r_g (P = 1.21 x 10^{-4}) with AN being significantly negatively correlated whilst BE-BROAD was not.

BE-BROAD and AN also diverged in their associations with anthropometric and metabolic traits. Waist-to-hip ratio showed significantly different SNP-r_g (P = 2.05 x 10^{-31}), with BE-BROAD being significantly positively correlated whilst AN was significantly negatively correlated. BE-BROAD showed a significantly stronger pattern of SNP-r_g with certain socio-demographic traits than AN (jackknife P < 2x10^{-4}), displaying negative genetic correlations with age at menarche and age at first birth in females, and positive genetic correlations with social deprivation and loneliness. In contrast, AN showed no significant SNP-r_g with these traits but was more strongly associated with educational traits such as college/university completion than BE-BROAD.

Figure 3 approximately here

Table 3 approximately here

Genetic signal in our BE-BROAD GWAS may partly be influenced by AN, given that 18% of our BE-BROAD cases have (known) AN (Supplementary Table 10). As a sensitivity analysis, we conducted an additional BE-BROAD GWAS, excluding cohorts that specifically focused on AN recruitment (Supplementary Results). The genetic correlation between BE-BROAD and the reduced GWAS did not differ from unity (0.96, SE 0.07), but genetic correlations with anthropometric traits were stronger in the reduced GWAS, suggesting that AN cases in the excluded cohorts may be masking this genetic signal (Supplementary Figure 17, Supplementary Table 11).

Role of BMI genetics

The role of BMI in eating disorders is complex, with low BMI being pathognomonic of AN and individuals with binge-eating disorder often being overweight [1]. If BMI is genetically causal of AN and BE (in opposite directions), then our GWASs would just be proxy GWASs for BMI. To assess this, we applied GWAS-by-subtraction to remove the genetic variance of BMI from BE-BROAD and from AN separately [15]. We modelled a factor shared between each eating disorder and BMI, and a *NonBMI* factor only loaded on by the eating disorder. The shared factor explained 12% (SE 2.7%) of genetic variance in BE-BROAD, leaving 88% (SE 7.9%) accounted for by the *NonBMI* factor. In AN, the shared factor accounted for 10% (SE 1.4%) of genetic variance, leaving 90% (SE 5.5%) accounted for by the *NonBMI* factor. GWASs of the *NonBMI* factor for BE-BROAD and for AN generally resulted in attenuated p-values for lead SNPs, but larger effect sizes in the same direction as the original GWAS (Figure 1, Supplementary Table 12).

We also conducted exploratory two-sample Mendelian randomisation analyses of BE-BROAD with BMI and AN with BMI, testing causal effects in both directions. We used SNPs in linkage equilibrium as genetic instruments, with $P < 5 \times 10^{-6}$ for BE-BROAD and AN, and $P < 5 \times 10^{-9}$ for BMI [16]. For each analysis, we used the full eating disorder GWAS, and the GWAS of the respective *NonBMI* component (Supplementary Results, Supplementary Table 13). Significant results were found in both directions between increased BE-BROAD risk and increased BMI risk. Increased BE-BROAD risk was still associated with increased BMI risk when using just the *NonBMI* component, but results were inconsistent across different MR methods when examining the effect of BMI risk on the *NonBMI* component of BE-BROAD. Significant results were found in both directions between increased AN risk and decreased BMI risk. However, the *NonBMI* component of AN risk was not associated with BMI risk, and results were inconsistent across MR methods when examining the effect of BMI risk on the *NonBMI* component of AN.

GWAS-by-subtraction also allowed us to explore the genetic architecture of the *NonBMI* component of BE-BROAD and AN through pairwise SNP-r_g with external traits (Supplementary Figure 18, Supplementary Table 14). Genetic correlations with psychiatric disorders typically remained stable or slightly increased relative to the respective full GWAS, while genetic correlations with anthropometric and metabolic traits were typically attenuated.

Genetically-regulated gene expression

We used S-PrediXcan [17] to identify predicted genetically-regulated gene expression associated with our phenotypes (Supplementary Figure 19; Supplementary Table 15). For BE-BROAD, two gene-tissue associations were significant at the experiment-wide threshold (*PRKAR2A*-Sigmoid colon and *KLHDC8B*-Heart, atrial appendage; $P < 8.32 \times 10^{-8}$). In AN, we observed 300 experiment-wide significant gene-tissue associations ($P < 8.32 \times 10^{-8}$) with 29 unique genes, predominantly from the gene-dense locus on chromosome 3 at 47-52Mb. Among the experiment-wide significant associations, 94 were in central nervous system tissues, and 41 in gastrointestinal tissues. Within-tissue significant results for both phenotypes are described in the Supplementary Results.

As a sensitivity analysis, we calculated cross-tissue predicted genetically-regulated gene expression using S-MultiXcan [17] to identify apparent tissue-specific associations that are better interpreted as tissue-general (Supplementary Results, Supplementary Figure 20, Supplementary Table 16). This showed ten genes with significant ($P < 2.25 \times 10^{-6}$) cross-tissue expression in BE-BROAD, four of which were also identified as tissue-level associations (including *KLHDC8B* but not *PRKAR2A*). Similarly, 43 genes showed significant cross-tissue expression in AN, of which 23 were identified as tissue-level associations.

Gene-level associations

We used MAGMA v1.10 [18] to conduct gene-wise analyses of the aggregate effect of SNPs mapped to protein-coding genes (Supplementary Table 17); gene-set analyses of

groups of genes with shared functional, biological, or other characteristics (Supplementary Table 18); and gene-set analyses restricted to genes targeted by medications (Supplementary Table 19; Supplementary Results). We also examined enrichment of signal within drug-sets belonging to the same class of drugs (Supplementary Table 20; Supplementary Results). In the gene analysis for BE-BROAD, MAGMA identified 22 genes significant after Bonferroni correction ($P < 2.59 \times 10^{-6}$). The *FTO* gene had the strongest association ($P = 2.8 \times 10^{-22}$) and 9/22 (43%) of the Bonferroni-significant genes were linked to the gene-dense locus on chromosome 3 at 47-52Mb. The MAGMA gene set, drug set, and drug-class analysis identified no Bonferroni-corrected significant gene sets for BE-BROAD. For AN, MAGMA identified 76 Bonferroni-corrected significant ($P < 2.58 \times 10^{-6}$) genes. The majority (54/76, 71%) of these genes were again mapped to chromosome 3 at 47-52Mb. The gene-set analysis identified enrichment of signal for AN in three biological pathways, related to the binding targets of RBFOX1-3 (RNA binding proteins that regulate neuronal alternative splicing [19]), and to mutation-constrained genes with pLI > 0.9. The drug-set analysis revealed no drug sets associated with AN, but antimigraine preparations as a class were significantly associated with AN.

Genes implicated both through proximity (MAGMA) and through effects on gene expression (S-PrediXcan) are more likely to be functionally relevant than those implicated through proximity alone [20]. We therefore further restricted our MAGMA gene-wise results to genes that were at least tissue-level significant in S-PrediXcan. This resulted in seven prioritised genes across four loci in BE-BROAD, and 38 prioritised genes across eight loci in AN (Supplementary Table 21; Supplementary Results).

Tissue and cell-type analyses

We used stratified LDSC [21] to estimate the enrichment of SNP-based heritability for BE-BROAD and AN among genes specifically expressed in GTEx human tissues (Supplementary Figure 21, Supplementary Table 22; Supplementary Results) and in human

brain cell types from the Human Brain Atlas (Supplementary Figure 22, Supplementary Table 23) [22,23]. After accounting for multiple testing, none of the associations was significant.

Polygenic prediction

We tested whether higher BE-BROAD and AN polygenic risk scores (PRS) were associated with a higher risk of BE-BROAD and AN, using a leave-one-cohort-out design targeted at well-powered cohorts representative of the ascertainment methods employed in the study (Methods; Supplementary Table 24). Individuals with 1 SD higher BE-BROAD PRS had an average odds ratio (OR) of 1.11 for BE-BROAD (average 95% confidence interval [CI] across cohorts: 1.08 – 1.14; *P* range: 2.38×10^{-15} - 0.022; Supplementary Figure 23). The average liability-scale variance explained was 0.32%. Individuals with 1 SD higher AN PRS had an average OR of 1.50 for AN (average 95% CI 1.42 – 1.59, all $P \times$ x 10^{-16}; Supplementary Figure 24) and AN PRS explained 2.32% liability-scale variance on average.

We additionally tested the cross-ancestry prediction of AN in two cohorts of East Asian ancestry from Korea and Japan. We found that the European AN PRS was positively associated with AN in the combined Korean and Japanese cohort, with an OR of 1.36 (95% CI 1.09 – 1.70, *P* = 0.0066), explaining 1.3% of the variance (assuming population prevalence of AN at 1.5%).

Next, we tested whether genetic risk of BE-BROAD and AN are shared across males and females, using a similar leave-one-cohort-out design. BE-BROAD PRS based on female-only GWAS were positively associated with BE-BROAD risk in males (OR ranges from 1.06 to 1.20), but not all results were significant, possibly due to low case numbers in some cohorts. Similarly, AN PRS calculated based on female-only GWAS were positively associated with AN risk in males (OR ranges from 1.07 to 1.41), but the results were not consistently significant (Supplementary Figure 25, Supplementary Table 25; Supplementary Results).

We further assessed if BE-BROAD and AN PRS differed across multiple cohorts comparing control individuals to (a) those with BE-BROAD only; (b) with both BE-BROAD and AN; and (c) with AN only. Overall, we found both BE-BROAD and AN PRS to be elevated in all subgroups compared to controls ($P \leq 0.024$). Among the subgroups, the comorbid and BE-BROAD-only groups did not significantly differ on BE-BROAD PRS, and typically had a significantly higher BE-BROAD PRS than the AN-only group (Supplementary Figure 26). The comorbid and AN-only groups did not significantly differ from each other on AN PRS, while the BE-BROAD-only group had a significantly lower AN PRS than both other groups in one cohort, but not in another (Supplementary Figure 26). Overall, our results suggest that AN patients with BE had elevated genetic risks of both BE-BROAD PRS and AN PRS (Supplementary Table 26; Supplementary Results).

DISCUSSION

Our results include the first six genomic loci to be implicated in BE, which have been previously associated with traits such as smoking [24], risk-taking behaviour [25], and age at menarche [26]. Overlap between BE and impulse-control behaviours was further observed in positive SNP-r_g with smoking, general risk tolerance, and problematic alcohol use. Loss of control is a key component of BE, and impulse-control behaviours have been associated with binge-type eating disorders clinically [27,28]. Alongside significant polygenic overlap with a range of psychiatric disorders, our findings imply that BE shares genetic underpinnings with psychiatric disorders and impulse-control behaviours.

Loci associated with BE-BROAD have also been implicated in anthropometric traits, including a BMI-related signal near *FTO* [16,29] that was not associated with AN or its subtypes. The *FTO* locus was first identified as being related to an elevated BMI in 2007 [30] and has thereafter been studied extensively (summarised in Loos et al. [31]). Six genes have been identified within the locus, but it has been challenging to determine the causal mechanism that contributes to a high BMI [31]. One study that investigated the complex relationship

between *FTO,* BMI, and BE found that *FTO* was related to BE independent of BMI [32], and suggested that BE could mediate the pathway between *FTO* and a high BMI. Together with our results, this implies that at least some of the relationship between *FTO* and high BMI stems from binge-eating behaviours.

For AN, we validated six previous loci, identified two new loci, and identified one locus for AN-R. The four single-gene loci that were identified in Watson et al. [7] remained genome-wide significant, suggesting that genes located in these regions—*CADM1, MGMT, FOXP1, PTBP2*—may warrant further investigation in the aetiology of AN. The AN-R-identified locus narrowly missed genome-wide significance in AN (P= 5.89 x 10^{-8}) and has previously been implicated in schizophrenia [33]. The locus contains several genes, of which distal-less homeobox 1 (*DLX1*) was indicated by both proximity-based and expression-based gene mapping*. DLX1* is differentially expressed in the brain and may be involved in several processes of neural development [34]. Further studies are needed to confirm that *DLX1* is implicated in AN-R aetiology, given the multigenic nature of the locus. Our gene-level results should generally be viewed cautiously, as greater power is needed to effectively fine-map associated loci and link causal variants to genes.

Despite increasing our effective sample size for AN by 64% since our previous freeze [7], we identified only two new loci, and two previously implicated loci were no longer genome-wide significant. We speculate that this is because our new cohorts were primarily population based and used more lenient case criteria compared to the clinical diagnoses and targeted AN-specific recruitment previously used [35]. Genetic signal also tends to become more heterogeneous as GWAS sample sizes increase [36,37].

While AN and BE have substantial symptomatological overlap and are both significantly heritable, key questions remain about their genetic relationships with other psychiatric, metabolic, and anthropometric traits. We have previously hypothesised that AN

is a metabo-psychiatric disorder [7]—this study yields for the first time the ability to investigate shared and distinct metabolic and psychiatric components across multiple eating disorders. BE-BROAD has typical genetic features of a psychiatric disorder, including significant shared SNP-r_g with psychiatric traits akin to previous findings [5,7,38,39]. The SNP-r_g pattern for BE is like that of AN, with notable exceptions. AN had a positive SNP-r_g with obsessive-compulsive disorder, whereas BE showed no significant association. Conversely, BE-BROAD was positively genetically correlated with ADHD, whilst AN showed no significant association. However, subtracting the shared genetic component between AN and BMI from AN resulted in a significant association between ADHD and AN, suggesting that opposing genetic correlations between AN and ADHD with BMI were previously masking this association.

When considering genetic correlations with non-psychiatric traits, we observed some key differences between AN and BE. BE-BROAD displayed a significantly stronger, negative genetic correlation with age at menarche whilst AN showed no genetic overlap, consistent with previous research [40]. This discrepancy may reflect findings that earlier age of menarche has been associated with more impulse-associated traits such as substance use and risk behaviour [41], which could arguably extend to binge eating, as well the finding in some observational studies find that later age of menarche is associated with AN [41,42].

Significant genetic correlations between BE-BROAD and anthropometric traits were positive compared with the negative genetic correlations observed in AN [38,39]. We observed patterns of significant SNP-r_g with BE concentrated in body composition and anthropometric features, while we validated our previous finding that significant SNP-r_gs with AN are concentrated in metabolic-related traits.

Eating disorders and their component features share genetic factors with anthropometric traits, but these effects act in opposite directions depending on the eating disorder presentation. To investigate this further, we assessed BE-BROAD and AN after subtracting the genetic component each shares with BMI. The BMI component only

accounted for 12% of the genetic variance of BE-BROAD and 10% of AN, despite low BMI being a diagnostic requirement for AN. A common concern with AN GWAS is that it is a BMI GWAS by proxy, as cases necessarily have lower BMI than controls; a similar argument could be made for BE cases having a higher BMI than controls. The low variance explained by the BMI component argues that neither of our eating disorder GWAS are BMI GWAS by proxy. This is further supported by the *FTO* locus association with BE-BROAD, which is observed in AN-ascertained cohorts where affected individuals are likely to have lower BMI than unaffected individuals. Consistent with previous literature [43], we also found no evidence for a genetic overlap between persistent thinness and AN, indicating that the cognitive-behavioural component of AN distinguishes these low-BMI phenotypes on a genomic level.

However, BMI is a blunt measure of body composition [44], and its relationship with eating disorders is complicated, with evidence that the negative genetic correlation between AN and BMI is driven by genetic enrichment for AN risk in individuals with very low BMIs, rather than a uniform linear relationship across BMIs [45]. Our GWASs likely reflect that both AN and BE are heterogeneous conditions, and subtypes may have differing relationships with BMI. Subtracting the BMI component from our eating disorder GWAS allows us tentative insights into the physiological aspects of these illnesses beyond their psychiatric aspects. However, more sophisticated analyses with a more diverse range of eating disorder presentations (including atypical AN in the normal BMI range) and of body composition measurements are needed to provide deeper understanding.

We present the first GWAS on BE, accompanied by the largest investigation of AN and AN subtypes to date, with chromosome X analysis included for all phenotypes. In so doing, we have extended genetic research into eating disorders beyond AN alone, and demonstrated that BE is a psychiatric phenotype with distinctive genetic relationships with external traits. Nonetheless, we warrant caution in interpreting our findings in light of the following limitations. First, our analyses are currently restricted to individuals of European

ancestry, limiting the generalizability of our results. We were able to extend PRS analyses to two small East Asian cohorts, but relied on European prevalence estimates for converting estimates of risk to the liability scale, which may introduce bias. Differences in population structure, genetic architecture, and environmental factors, such as lower average BMI in Korean and Japanese populations, could influence the cross-ancestry prediction of AN. More GWAS and PRS studies in East Asian populations are required to improve the accuracy of genetic risk predictions and better understanding of the genetic factors influencing AN in these populations.

This limitation extends to global ancestries and should be considered from both phenotypic and genotypic perspectives [46]. A historic focus of eating disorder studies in European populations may have skewed understanding and definitions of disease presentation, overemphasising certain diagnostic criteria over others, and perpetuating exclusion from studies due to stereotyping of eating disorder presentations as they occur in young, white women. From a genotypic perspective, exclusion in our studies precludes elucidation of the full genetic architecture of the trait, with a narrow focus on variants of common frequency in European populations. Ongoing collection efforts for newer studies will broaden our focus substantially, with an emphasis on community co-production, global collection, and involvement of other historically excluded groups in eating disorder research, including people of colour, men, the LGBTQIA+ community, and people living in larger bodies. We are actively working towards a fuller recognition of the diversity of humanity in eating disorders genetic research.

Second, given the known diagnostic migration across the eating disorders, cohorts that contributed cross-sectional diagnoses or symptoms only are unable to account for later development of a disorder or symptom; for example, an individual with AN-R might go on to develop AN-BP [3]. It is not possible to fully mitigate this limitation. However: (1) many of our cohorts include individuals well beyond the typical initial age of diagnosis, making new diagnoses or diagnostic migration less likely; (2) hidden diagnostic migration likely

contributes to false negatives and under-estimation of differences between GWAS, rather than introducing false positives [47]; and (3) our previous work has shown that rates of diagnostic contamination (a similar effect to hidden diagnostic migration) would need to occur at extremely high levels to affect locus discovery [48].

A third, related limitation is that heterogeneity might exist within the phenotypes due to factors such as distinct methods of ascertainment, despite our best effort to harmonise the phenotypes. The optimal approach to harmonisation would be to include individuals from a single ascertainment source (e.g., structured diagnostic interviews), but the gain in sample size through including multiple ascertainment approaches can increase power despite the resulting heterogeneity. Thus, one must balance the advantages of data availability with the uniformity of a phenotype. Fourth, our sample consists of predominantly females, and results may not necessarily generalise to males or intersex individuals. Finally, although strongly associated with BE-BROAD and AN risk, polygenic risk scores remain very weak predictors of BE-BROAD and AN status. Combining PRS with other risk factors is needed to further improve prediction accuracy of AN and BE-BROAD.

Historically, binge-type eating disorders have been overshadowed by research on AN despite their higher prevalence. This paper seeks to redress that imbalance. We identified six genetic loci relating to broadly defined BE, validated six loci related to AN, reported two novel loci, and found one locus related to the restricting subtype of AN. We demonstrate that BE is genetically related to several other psychiatric phenotypes, with both shared and distinct patterns as seen with AN, providing genetic substantiation of comorbidity patterns seen in AN compared with binge-type eating disorders. Additionally, we conducted comprehensive analyses to explore phenotypic diversity within these disorders. Our focus on the transdiagnostic symptom of BE recognises the fluidity of diagnoses and the potentially arbitrary boundaries we draw between them, enabling the elucidation of both shared and unique genetic features that distinguish eating disorder presentations [49].

References

1. Association, A. P. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5®).* (American Psychiatric Pub, 2013).

2. Schaumberg, K. *et al.* Patterns of diagnostic transition in eating disorders: a longitudinal population study in Sweden. *Psychol. Med.* **49**, 819–827 (2019).

3. Abdulkadir, M. *et al.* Descriptives and genetic correlates of eating disorder diagnostic transitions and presumed remission in the Danish registry. *medRxiv* (2024) doi:10.1101/2024.09.05.24313142.

4. Wang, K. *et al.* A genome-wide association study on common SNPs and rare CNVs in anorexia nervosa. *Mol. Psychiatry* **16**, 949–959 (2011).

5. Duncan, L. *et al.* Genome-Wide Association Study Reveals First Locus for Anorexia Nervosa and Metabolic Correlations. *BioRxiv* (2016) doi:10.1101/088815.

6. Boraska, V. *et al.* A genome-wide association study of anorexia nervosa. *Mol. Psychiatry* **19**, 1085–1094 (2014).

7. Watson, H. J. *et al.* Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nat. Genet.* **51**, 1207–1214 (2019).

8. Arcelus, J., Mitchell, A. J., Wales, J. & Nielsen, S. Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies. *Arch. Gen. Psychiatry* **68**, 724–731 (2011).

9. Bulik, C. M. *et al.* Understanding the relation between anorexia nervosa and bulimia nervosa in a Swedish national twin sample. *Biol. Psychiatry* **67**, 71–77 (2010).

10. Lilenfeld, L. R. *et al.* A controlled family study of anorexia nervosa and bulimia nervosa: psychiatric disorders in first-degree relatives and effects of proband comorbidity. *Arch. Gen. Psychiatry* **55**, 603–610 (1998).

11. Hudson, J. I., Hiripi, E., Pope, H. G. & Kessler, R. C. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. *Biol. Psychiatry* **61**,

348–358 (2007).

12. Loh, P.-R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model association for biobank-scale datasets. *Nat. Genet.* **50**, 906–908 (2018).

13. Galmiche, M., Déchelotte, P., Lambert, G. & Tavolacci, M. P. Prevalence of eating disorders over the 2000-2018 period: a systematic literature review. *Am. J. Clin. Nutr.* **109**, 1402–1413 (2019).

14. Peyrot, W. J. & Price, A. L. Identifying loci with different allele frequencies among cases of eight psychiatric disorders using CC-GWAS. *Nat. Genet.* **53**, 445–454 (2021).

15. Demange, P. *et al.* Investigating the genetic architecture of noncognitive skills using GWAS-by-subtraction. *Nat. Genet.* **53**, 35–44 (2021).

16. Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum. Mol. Genet.* **28**, 166–174 (2019).

17. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).

18. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).

19. Fisher, E. & Feng, J. RNA splicing regulators play critical roles in neurogenesis. *Wiley Interdiscip. Rev. RNA* **13**, e1728 (2022).

20. Forgetta, V. *et al.* An effector index to predict target genes at GWAS loci. *Hum. Genet.* **141**, 1431–1447 (2022).

21. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).

22. Siletti, K. *et al.* Transcriptomic diversity of cell types across the adult human brain. *Science* **382**, eadd7046 (2023).

23. Yao, S. *et al.* Connecting genomic results for psychiatric disorders to human brain cell

types and regions reveals convergence with functional connectivity. *Nat. Commun.* **16**, 395 (2025).

24. Pasman, J. A. *et al.* Genetic risk for smoking: disentangling interplay between genes and socioeconomic status. *Behav. Genet.* **52**, 92–107 (2022).

25. Baselmans, B. *et al.* The Genetic and Neural Substrates of Externalizing Behavior. *Biol Psychiatry Glob Open Sci* **2**, 389–399 (2022).

26. Pickrell, J. K. *et al.* Detection and interpretation of shared genetic influences on 42 human traits. *Nat. Genet.* **48**, 709–717 (2016).

27. Farstad, S. M. *et al.* The influence of impulsiveness on binge eating and problem gambling: A prospective study of gender differences in Canadian adults. *Psychol. Addict. Behav.* **29**, 805–812 (2015).

28. Meule, A. & Platte, P. Facets of impulsivity interactively predict body fat and binge eating in young women. *Appetite* **87**, 352–357 (2015).

29. Bradfield, J. P. *et al.* A trans-ancestral meta-analysis of genome-wide association studies reveals loci associated with childhood obesity. *Hum. Mol. Genet.* **28**, 3327–3338 (2019).

30. Frayling, T. M. *et al.* A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* **316**, 889–894 (2007).

31. Loos, R. J. F. & Yeo, G. S. H. The genetics of obesity: from discovery to biology. *Nat. Rev. Genet.* **23**, 120–133 (2022).

32. Micali, N., Field, A. E., Treasure, J. L. & Evans, D. M. Are obesity risk genes associated with binge eating in adolescence? *Obesity (Silver Spring)* **23**, 1729–1736 (2015).

33. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* **604**, 502–508 (2022).

34. Letinic, K., Zoncu, R. & Rakic, P. Origin of GABAergic neurons in the human neocortex. *Nature* **417**, 645–649 (2002).

35. Thornton, L. M. *et al.* The Anorexia Nervosa Genetics Initiative (ANGI): Overview and

methods. *Contemp. Clin. Trials* **74**, 61–69 (2018).

36. de Vlaming, R. *et al.* Meta-GWAS Accuracy and Power (MetaGAP) Calculator Shows that Hiding Heritability Is Partially Due to Imperfect Genetic Correlations across Studies. *PLoS Genet.* **13**, e1006495 (2017).

37. Wang, X. *et al.* Polygenic risk prediction: why and when out-of-sample prediction R2 can exceed SNP-based heritability. *Am. J. Hum. Genet.* **110**, 1207–1215 (2023).

38. Hübel, C. *et al.* One size does not fit all. Genomics differentiates among anorexia nervosa, bulimia nervosa, and binge-eating disorder. *Int. J. Eat. Disord.* **54**, 785–793 (2021).

39. Abdulkadir, M. *et al.* Eating disorder symptoms and their associations with anthropometric and psychiatric polygenic scores. *Eur. Eat. Disord. Rev.* **30**, 221–236 (2022).

40. Watson, H. J. *et al.* Common genetic variation and age of onset of anorexia nervosa. *Biological Psychiatry Global Open Science* **2**, 368–378 (2022).

41. Padrutt, E. R. *et al.* Pubertal timing and adolescent outcomes: investigating explanations for associations with a genetically informed design. *J. Child Psychol. Psychiatry* **64**, 1232–1241 (2023).

42. Klump, K. L. Puberty as a critical risk period for eating disorders: a review of human and animal studies. *Horm. Behav.* **64**, 399–410 (2013).

43. Hübel, C. *et al.* Persistent thinness and anorexia nervosa differ on a genomic level. *Eur. J. Hum. Genet.* **32**, 117–124 (2024).

44. Müller, M. J. From BMI to functional body composition. *Eur. J. Clin. Nutr.* **67**, 1119–1121 (2013).

45. Akingbuwa, W. & Nivard, M. W27. modelling non-linearity in bivariate genetic relationships. *Eur. Neuropsychopharmacol.* **87**, 115 (2024).

46. Huckins, L. M. *et al.* What next for eating disorder genetics? Replacing myths with facts to sharpen our understanding. *Mol. Psychiatry* **27**, 3929–3938 (2022).

47. Dueñas, H. R., Seah, C., Johnson, J. S. & Huckins, L. M. Implicit bias of encoded variables: frameworks for addressing structured bias in EHR-GWAS data. *Hum. Mol. Genet.* **29**, R33–R41 (2020).

48. Johnson, J. S. *et al.* Mapping anorexia nervosa genes to clinical phenotypes. *Psychol. Med.* **53**, 2619–2633 (2023).

49. Tiego, J. *et al.* Precision behavioral phenotyping as a strategy for uncovering the biological correlates of psychopathology. *Nat. Ment. Health* **1**, 304–315 (2023).

50. Lam, M. *et al.* RICOPILI: rapid imputation for consortias pipeline. *Bioinformatics* **36**, 930–933 (2020).

51. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290–299 (2021).

52. Loh, P.-R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat. Genet.* **48**, 1443–1448 (2016).

53. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1284–1287 (2016).

54. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* **48**, 1279–1283 (2016).

55. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).

56. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).

57. Chen, W. *et al.* Improved analyses of GWAS summary statistics by reducing data heterogeneity and errors. *Nat. Commun.* **12**, 7117 (2021).

58. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).

59. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–75, S1

(2012).

60. Purcell, S., Cherny, S. S. & Sham, P. C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* **19**, 149–150 (2003).

61. Ekeroth, K., Clinton, D., Norring, C. & Birgegård, A. Clinical characteristics and distinctiveness of DSM-5 eating disorder diagnoses: findings from a large naturalistic clinical database. *J. Eat. Disord.* **1**, 31 (2013).

62. Bulik-Sullivan, B. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

63. International HapMap 3 Consortium *et al.* Integrating common and rare genetic variation in diverse human populations. *Nature* **467**, 52–58 (2010).

64. Grotzinger, A. D., Fuente, J. de la, Privé, F., Nivard, M. G. & Tucker-Drob, E. M. Pervasive Downward Bias in Estimates of Liability-Scale Heritability in Genome-wide Association Study Meta-analysis: A Simple Solution. *Biol. Psychiatry* **93**, 29–36 (2023).

65. Barbeira, A. N. *et al.* Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. *Genome Biol.* **22**, 49 (2021).

66. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference transcriptome data. *Nat. Genet.* **47**, 1091–1098 (2015).

67. Huckins, L. M. *et al.* Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. *Nat. Genet.* **51**, 659–674 (2019).

68. Team, P. CommonMind consortium - Brain Dorsolateral Prefrontal Cortex. (2019).

69. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318–1330 (2020).

70. Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues improves association detection. *PLoS Genet.* **15**, e1007889 (2019).

71. Gaspar, H. A. & Breen, G. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. *Sci. Rep.* **7**, 12460

(2017).

72. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).

73. Freshour, S. L. *et al.* Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. *Nucleic Acids Res.* **49**, D1144–D1151 (2021).

74. Roth, B. L., Lopez, E., Patel, S. & Kroeze, W. K. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? *Neuroscientist* **6**, 252–262 (2000).

75. Mendez, D. *et al.* ChEMBL: towards direct deposition of bioassay data. *Nucleic Acids Res.* **47**, D930–D940 (2019).

76. Sheils, T. K. *et al.* TCRD and Pharos 2021: mining the human proteome for disease biology. *Nucleic Acids Res.* **49**, D1334–D1346 (2021).

77. Yoo, M. *et al.* DSigDB: drug signatures database for gene set analysis. *Bioinformatics* **31**, 3069–3071 (2015).

78. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. (2023).

79. GTEx Consortium *et al.* Genetic effects on gene expression across human tissues. *Nature* **550**, 204–213 (2017).

80. Bryois, J. *et al.* Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease. *Nat. Genet.* **52**, 482–493 (2020).

81. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).

82. Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).

83. Hübel, C. *et al.* Genomics of body fat percentage may contribute to sex bias in anorexia

nervosa. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **180**, 428–438 (2019).

84. Grotzinger, A. D. *et al.* Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. *Nat. Hum. Behav.* **3**, 513–525 (2019).

85. Core Team, R. & Others. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. *Available* (2013).

86. Aschard, H., Vilhjálmsson, B. J., Joshi, A. D., Price, A. L. & Kraft, P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. *Am. J. Hum. Genet.* **96**, 329–339 (2015).

87. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7**, (2018).

88. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat. Genet.* **50**, 693–698 (2018).

89. Haycock, P. C. *et al.* Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. *Am. J. Clin. Nutr.* **103**, 965–978 (2016).

90. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* **44**, 512–525 (2015).

91. Rees, J. M. B., Wood, A. M., Dudbridge, F. & Burgess, S. Robust methods in Mendelian randomization via penalization of heterogeneous causal estimates. *PLoS ONE* **14**, e0222362 (2019).

92. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).

93. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).

94. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk

score analyses. *Nat. Protoc.* **15**, 2759–2772 (2020).

95. Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of determination for genetic profile analysis. *Genet. Epidemiol.* **36**, 214–224 (2012).

96. Robin, X. *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* **12**, 77 (2011).

97. CRAN: Package pracma. https://doi.org/10.32614/CRAN.package.pracma.

98. Nakai, Y., Nin, K. & Goel, N. J. The changing profile of eating disorders and related sociocultural factors in Japan between 1700 and 2020: A systematic scoping review. *Int. J. Eat. Disord.* **54**, 40–53 (2021).

Table 1

Phenotype	Inclusion criteria	Diagnostic codes	
AN-R *AN - restricting subtype*	1. A clinical diagnosis of AN restricting subtype via hospital/register records, structured clinical interviews, or online questionnaires based on standardised criteria, or; 2. A self-reported diagnosis of AN restricting subtype, confirmation by healthcare professional not required	ICD-10 DSM 5	F50.01 (ICD-10); 307.1 [F50.01] (DSM-5)
AN-BP *AN - binge-eating/ purging subtype*	1. A clinical diagnosis of AN binge-eating/purging subtype via hospital/register records, structured clinical interviews, or online questionnaires based on standardised criteria, or; 2. A self-reported diagnosis of AN binge-eating/purging subtype, confirmation by healthcare professional not required	ICD-10 DSM 5	F50.02 (ICD-10); 307.1 [F50.02] (DSM-5)
AN *AN - no subtype specified* (incl. AN-R and AN-BP)	1. A clinical diagnosis of AN / AN binge-eating/purging subtype / AN restricting subtype via hospital/register records, structured clinical interviews, or online questionnaires based on standardised criteria, or; 2. A self-reported diagnosis of AN / AN binge-eating/purging subtype / AN restricting subtype, confirmation by healthcare professional not required. Note: atypical AN (without significantly low body weight) was not specifically excluded from our analyses, but has been historically ill-defined and was not ascertained for in most cohorts. As such, our AN data primarily reflect typical AN.	ICD-8 ICD-9 ICD-10 DSM-III-R DSM-IV DSM 5	306.50 (ICD-8); 307.1 (ICD-9, DSM-III-R, DSM-IV); F50.0 (ICD-10); F50.1 (ICD-10); 307.1 [F50.1] (DSM-5)
BE-NARROW *Binge-eating - narrowly defined*	1. Eating an unusually large amount of food in a short period of time with loss of control, and these episodes occurred on average at least once a week for at least three months, or; 2. A clinical diagnosis of bulimia nervosa or binge-eating disorder via hospital/register records or a structured clinical interview, or; 3. A self-reported diagnosis of bulimia nervosa or binge-eating disorder with confirmation by a healthcare professional.	ICD-9 ICD-10 DSM-III-R DSM-IV DSM 5	307.51 (ICD-9, DSM-III-R, DSM-IV); F50.2 (ICD-10); F50.81 (ICD-10-CM); 307.51 [F50.2] (DSM-5)
BE-BROAD *Binge-eating - broadly defined* (incl. BE-NARROW)	1. Eating an unusually large amount of food in a short period of time with loss of control. Frequency and duration criteria not required, or; 2. If assessed by a single item like "Have you ever experienced binge-eating?"*; 3. A self-reported diagnosis of bulimia nervosa or binge-eating disorder, confirmation by healthcare professional not required**.	ICD-9 ICD-10 DSM-III-R DSM-IV DSM 5	307.51 (ICD-9, DSM-III-R, DSM-IV); F50.2 (ICD-10); F50.3 (ICD-10); 307.51 [F50.2] (DSM-5); 307.51 [F50.3] (DSM-5); F50.81 (ICD-10-CM)
Controls	1. No history of any eating disorder and no history of binge-eating (broadly or narrowly defined), or; 2. No history of any eating disorder, or; 3. Unscreened (i.e., these individuals may have had an eating disorder or binge-eating).		

Table 1: Phenotype definitions. Diagnostic codes are shown with coding system in round brackets, and equivalent codes in square brackets. Control definitions are shown in order of preference.
Footnotes: *If assessed with terms such as "psychological overeating", "compulsive eating", etc., these individuals will not be included as BE-BROAD cases. **If Other Specified Feeding or Eating Disorder or Eating Disorder Not Otherwise Specified is diagnosed, these are included only if clearly stated 'subthreshold bulimia nervosa' or 'subthreshold binge-eating disorder'.

Table 2.

Phenotype	Locus	CHR	Locus Start	Locus End	Lead SNP	P	REF/ALT	OR	SE	ALT Freq Cases	ALT Freq Controls	INFO	Previously associated	Genes
BE-BROAD	1	1	74,977,295	75,014,362	rs7541513	3.02×10^{-9}	G/A	1.05	0.009	0.427	0.425	0.952	-	*LRRC53 / TNNI3K*
	2	3	117,420,697	117,953,697	rs1456193	3.42×10^{-8}	T/C	1.06	0.011	0.808	0.802	0.996	-	Intergenic
	3	11	93,171,140	93,231,940	rs2925354	4.91×10^{-8}	G/A	0.93	0.013	0.107	0.112	0.995	-	*DEUP1 / SMCO4*
	4	12	50,169,080	50,285,780	rs7953534	1.42×10^{-8}	G/A	1.05	0.009	0.351	0.333	0.985	-	Multigenic
	5	16	53,797,904	53,845,494	rs11642015	4.13×10^{-17}	C/T	1.07	0.009	0.429	0.417	1.000	-	*FTO*
	6	18	57,730,978	57,914,978	rs66723169	5.24×10^{-9}	C/A	1.06	0.010	0.254	0.209	0.995	-	Intergenic
AN	1	1	96,700,455	97,285,455	rs10747478	1.43×10^{-8}	T/G	0.94	0.011	0.570	0.587	0.998	Yes[20]	PTBP2
	2	3	47,501,450	51,741,450	rs113519699	2.86×10^{-18}	A/C	1.18	0.019	0.102	0.087	0.997	Yes[20]	Multigenic
	3	3	70,602,234	71,074,242	rs9310201	3.12×10^{-12}	A/T	1.08	0.011	0.427	0.408	0.982	Yes[20]	FOXP1
	4	5	24,868,440	25,300,440	rs6872919	1.07×10^{-9}	A/C	1.07	0.011	0.570	0.532	0.997	Yes[20]	Intergenic
	5	10	75,850,972	76,524,972	rs10740439	1.91×10^{-9}	C/T	0.93	0.012	0.711	0.716	0.994	No	Multigenic
	6	10	131,274,055	131,459,255	rs12762024	3.28×10^{-9}	G/C	1.07	0.011	0.447	0.455	0.995	Yes[20]	*MGMT*
	7	11	114,997,256	115,284,956	rs6589488	9.80×10^{-9}	A/T	0.91	0.016	0.846	0.875	0.990	Yes[20]	*CADM1*
	8	12	17,635,314	17,965,314	rs12817084	8.93×10^{-9}	T/C	1.10	0.011	0.115	0.117	0.991	No	Intergenic

Table 2: Association statistics for genome-wide significant loci for BE-BROAD and AN. Loci are numbered sequentially within-analysis from chromosome 1 to chromosome X. Base pair start and end positions correspond to hg19. Odds ratios (OR) are given relevant to the ALT allele.

Table 3

Trait	Category	PMID	rg (AN)	SE (AN)	*P* (AN)	rg (BE)	SE (BE)	*P* (BE)
BMI	Anthropometric	30239722	-0.31	0.020	**2.37×10^{-56}**	0.36	0.032	**1.94×10^{-28}**
Body fat %	Anthropometric	30593698	-0.35	0.028	**2.71×10^{-36}**	0.20	0.042	**2.65×10^{-6}**
Fat free mass	Anthropometric	30593698	-0.15	0.022	**2.93×10^{-11}**	0.30	0.034	**6.92×10^{-19}**
Fat mass	Anthropometric	31852892	-0.32	0.023	**3.63×10^{-43}**	0.31	0.035	**1.36×10^{-18}**
Persistent thinness	Anthropometric	30677029	0.11	0.074	0.123	-0.46	0.110	**2.37×10^{-5}**
Pubertal growth (height diff, 8 years-adult)	Anthropometric	23449627	-0.03	0.053	0.606	-0.37	0.079	**3.08×10^{-6}**
Severe early-onset obesity	Anthropometric	30677029	-0.11	0.059	0.0587	0.48	0.080	**1.40×10^{-9}**
Waist-hip ratio	Anthropometric	30239722	-0.25	0.021	**1.72×10^{-34}**	0.19	0.034	**1.37×10^{-8}**
Waist-hip ratio (BMI-adj)	Anthropometric	30239722	-0.09	0.020	**9.33×10^{-6}**	-0.05	0.033	0.119
Fasting insulin (age- & sex-adj)	Metabolism	33402679	-0.30	0.048	**2.79×10^{-10}**	0.15	0.069	0.0292
Fasting insulin (BMI-adj)	Metabolism	34059833	-0.17	0.035	**9.62×10^{-7}**	-0.29	0.047	**6.29×10^{-10}**
HbA1c	Metabolism	28898252	-0.14	0.042	6.00×10^{-4}	-0.03	0.053	0.5242
HbA1c (BMI-adj)	Metabolism	34059833	-0.16	0.034	**5.22×10^{-6}**	0.01	0.044	0.765
Type 2 diabetes	Metabolism	30297969	-0.18	0.024	**1.76×10^{-14}**	0.11	0.040	6.10×10^{-3}
ADHD	Psychiatric	36702997	0.07	0.029	0.0126	0.31	0.042	**2.20×10^{-13}**
Autism	Psychiatric	32747698	0.17	0.044	**1.00×10^{-4}**	0.29	0.057	**3.96×10^{-7}**
Bipolar disorder	Psychiatric	34002096	0.25	0.027	**3.80×10^{-21}**	0.23	0.035	**4.22×10^{-11}**
Insomnia	Psychiatric	30804565	0.10	0.033	2.90×10^{-3}	0.21	0.044	**2.02×10^{-6}**
MDD	Psychiatric	29700475	0.29	0.059	**6.43×10^{-7}**	0.25	0.074	7.00×10^{-4}
OCD	Psychiatric	28761083	0.48	0.069	**2.85×10^{-12}**	0.08	0.081	0.322
Probable anxiety diagnosis	Psychiatric	31748690	0.28	0.039	**1.42×10^{-12}**	0.32	0.060	**1.03×10^{-7}**
PTSD	Psychiatric	33510476	0.11	0.049	0.0274	0.24	0.062	**1.00×10^{-4}**
Schizophrenia	Psychiatric	35396580	0.24	0.021	**4.85×10^{-30}**	0.23	0.033	**7.04×10^{-12}**
General risk tolerance	Behavioural	30643258	0.00	0.028	0.991	0.21	0.040	**6.76×10^{-8}**
Loneliness	Behavioural	31518406	0.13	0.032	**4.96×10^{-5}**	0.37	0.044	**4.14×10^{-17}**
Physical activity	Behavioural	36071172	0.19	0.034	**5.87×10^{-8}**	0.09	0.046	0.0633
Educational attainment (years)	Socio-demographic	30038396	0.25	0.022	**1.25×10^{-29}**	0.04	0.030	0.1417
AUDIT-P	Substance use	30336701	0.01	0.040	0.870	0.37	0.057	**7.00×10^{-11}**
Cannabis use disorder	Substance use	33096046	0.02	0.046	0.610	0.30	0.063	**2.78×10^{-6}**
Heavy smoker	Substance use	28166213	-0.04	0.039	0.255	0.30	0.048	**3.82×10^{-10}**
Lifetime cannabis use	Substance use	30150663	0.22	0.038	**8.48×10^{-9}**	0.32	0.051	**6.36×10^{-10}**

Table 3: Selected genetic correlations of BE-BROAD and AN with external traits.
PMID = PubMed ID of GWAS for external trait.

Figure 1: Miami plots showing results from the AN (top) and BE-BROAD (bottom) meta-analyses. The dotted red line is the genome-wide significance threshold ($P \leq 5 \times 10^{-8}$).
a. Main GWAS analyses, with variants reaching genome-wide significance coloured in blue if significant in the anorexia nervosa GWAS and in purple if significant in the binge eating broad GWAS. Variants reaching genome-wide significance in CC-GWAS analyses of AN vs BE-BROAD are coloured in red.
b. GWAS-by-subtraction analyses, showing results from the non-BMI genetic component. Variants reaching genome-wide significance coloured in blue for anorexia nervosa non-BMI component and purple in binge eating non-BMI component.

Figure 2: Genetic distance between cases and controls of anorexia nervosa (AN) and binge eating broad (BEB) estimated by CC-GWAS analysis. The genetic distance, ‾‾‾‾‾‾‾ is calculated by taking the square root of the product of *m*, the number of independent causal variants estimated here as 10,000 based on the polygenic nature of AN and BEB, and ‾‾‾‾‾‾‾ derived based on the SNP-based heritabilities, genetic correlations, and population prevalences of the two traits

Figure 3: Genetic correlations (rg) of external traits with AN and BE-BROAD, split by those that are non-significantly different from each other (left panel) and those that are significantly different from each other (right panel). The left panel is further broken down into traits that have a significant rg with both AN and BE-BROAD (top), traits that have a significant rg only with AN (middle), and traits that have a significant rg only with BE-BROAD (bottom). The right panel is further broken down into traits in which the rg with AN is greater than the rg with BE-BROAD (top), and traits in which the rg with BE-BROAD is greater than the rg with AN (bottom). The rgs were computed by Linkage Disequilibrium Score Regression (LDSC). The rg estimation is indicated by the dot and standard errors are indicated by the lines on either side of each dot. rg estimates have been corrected for multiple testing via the Bonferroni method. Information about the summary statistics used in our analysis can be found in Supplementary Table 8.
AN = anorexia nervosa; BE BROAD = binge-eating broad definition; MDD = major depressive disorder; PGC = Psychiatric Genomics Consortium; BMI = Body mass index; F = female; M = male; FFM = fat-free mass; AUDIT-P = Alcohol Use Disorder Identification Test problem items.

METHODS

Ethics

  The individual studies that comprise this investigation were conducted with advance approval by the appropriate Institutional Review Boards or equivalents at the individual study sites. We provide ethical statements for each study site in the Supplementary Note. This work represents a secondary analysis with data from these individual studies.

Summary of cohorts

  Detailed descriptions of the ascertainment and definition of cases and controls for each cohort is provided in Supplementary Table 1. Broadly, we identified cases and controls based on clinical diagnoses, diagnostic algorithms, and/or self-report questionnaires [35]. We defined controls as individuals without a history of BE and without a history of an eating disorder, if possible. If this information was unavailable, unscreened controls were included assuming that the large control numbers would outweigh the impact of misclassified individuals in the control groups, given the collective lifetime prevalence of eating disorders is ~5% [13].

  We included data from the Psychiatric Genomics Consortium Eating Disorder Working Group (PGC-ED; Supplementary Table 1). These data were restricted to individuals of European ancestry due to the limited availability of non-European ancestry samples at the time of analysis—we included two cohorts with individuals of East Asian ancestry for follow-up cross-ancestry polygenic risk score analyses. In total, we combined 27 European ancestry datasets totalling 14 previously analysed [7] and 13 new cohorts. Data from cohorts providing individual-level data (n=11) were combined with cohorts that contributed summary statistics (n=16; Supplementary Table 1). Detailed descriptions of each of the cohorts are provided in the Supplementary Note. We included data if the total number of cases for any phenotype prior to quality control was >100. If cases for an individual phenotype were <50, we excluded that phenotype from analyses.

We include five different phenotypes: BE broadly defined (BE-BROAD, 39,279 cases), BE narrowly defined (BE-NARROW, 15,175 cases), AN (n = 24,145 cases), AN restricting subtype (AN-R, 2,524 cases), and AN binge-eating/purging subtype (AN-BP, 5,245 cases). Detailed phenotypic definitions are provided in Table 1.

Pre-imputation genotype quality control

Information about genotyping platforms for each cohort is documented in Supplementary Tables 4. Individual-level genotyping data were available from our previous GWAS meta-analysis and quality control is detailed therein and in the Supplementary Methods [7]. In brief, quality control of single-nucleotide polymorphisms (SNPs) and individuals in each cohort was conducted following established protocols [50]. This resulted in data on unrelated individuals with high call rates (≥ 98%), with concordant phenotypic and genotypic sex information, which were homogenous on principal components derived from genome-wide genotypes (consistent with similar genetic ancestry). Genotypic data consisted of polymorphic SNPs with high call rates (≥ 98%) consistent between cases and controls, and not deviating from Hardy-Weinberg equilibrium. Chromosome X data were available for a subset of cohorts (Supplementary Table 4). We restricted chromosome X analyses to individuals included in the autosomal analysis and conducted quality control as for autosomal SNPs.

Summary-level data were available from contributing cohorts (Supplementary Table 1). Quality control of these datasets followed a basic shared protocol, with deviations as necessary for each cohort (Supplementary Methods). In general, quality control was consistent with that described above for individual-level data cohorts. An exception to this was that some cohorts conducted analyses using mixed linear models, and so did not exclude related participants from their data.

Imputation

For all individual-level data cohorts where patient consent and national data privacy laws allowed, autosomal and chromosome X genotypes were imputed to TOPMed freeze 8 [51] using Minimac4, and phasing was performed with Eagle 2.4 [52] via the TOPMed Imputation Server [53]. For individual-level data cohorts that could not be imputed to TOPMed, we imputed to the Haplotype Reference Consortium (HRC) [54] using Minimac3, with phasing conducted via Eagle v2.3.5, implemented in the Ricopili pipeline [50]. Cohorts supplying summary statistics used TOPMed, HRC, or in some cases used bespoke imputation reference panels (Supplementary Table 4). We plotted imputation INFO scores against various MAF bins to check imputation quality, and we assessed missingness for each MAF bin.

Association analyses

The statistical model used to conduct the GWAS for each cohort (described in Supplementary Table 4) depended on the design of the specific cohort. For unrelated case/control cohorts, we used PLINK2 to conduct logistic regression using an appropriate number of PCs to account for ancestry as necessary within each cohort (Supplementary Table 4). For related or imbalanced case/control cohorts we used SAIGE [55] or REGENIE [56]. Note that for whole genome regression in REGENIE step 1, we used a set of pruned SNPs with MAF > 0.01, excluding high LD regions and only including autosomal chromosomes (PLINK command: --indep-pairwise 1500 150 0.2). Further details on cohort-specific aspects of association analysis are provided in the Supplementary Methods.

Post-GWAS processing and quality control

We aligned the summary statistics of each GWAS to the TOPMed reference panel in Genome Reference Consortium Build 37 (GRCh37/hg19), using variant positions from ENSEMBL (see URLs). For cohorts that were in GRCh38, we first linked the datasets with

the GRCh38 TOPMed reference panel (see URLs) by chromosome/base pair, then selected

the SNP rsID labels and linked these labels to the GRCh37 TOPMed reference panel, and

finally extracted the GRCh37 chromosome/base pair information for each SNP. Variants

without a rsID label in the GRCh38 TOPMed reference panel were lifted over to GRCh37

using the liftOver tool (see URLs). After alignment, we applied an INFO and MAF filter to

include SNPs with an INFO score of > 0.3 and MAF > 0.01 in cases and controls. We then

used DENTIST [57] to remove variants with effects inconsistent with their linkage

disequilibrium pattern with other assessed variants, estimating linkage disequilibrium from

European ancestry individuals in Phase 3 of the 1000 Genomes project.

Meta-analysis and quality control

We used the post-imputation module of RICOPILI version 2019, Oct. [50], to perform

meta-analyses in METAL [58] using an inverse-variance weighted fixed-effect model. We

define independent significant SNPs as SNPs with a genome-wide significant P-value (P < 5

x 10^{-8}) that are independent (r^2 > 0.6) from each other. We then define significant genomic

loci by merging LD blocks of these independent significant SNPs if they are close to each

other (< 250 kb). Furthermore, we define independent lead SNPs if independent significant

SNPs are independent of each other at r^2 < 0.1.

We ran a stepwise conditional analysis on our GWAS results to select independently-

associated SNPs at each loci using GCTA-COJO [59]. For these analyses we used one of our

largest cohorts (*usa2*) as our reference for linkage disequilibrium.

Power analysis

We estimated what magnitude of relative risk we were powered to detect using

Genetic Power Calculator [60]. Assuming perfect linkage disequilibrium between the marker

and the risk SNP (D' = 1), we set the number of cases to ½ N_{eff} (Supplementary Table 1) and

the control:case ratio to 1. We specified lifetime risk as follows: BE-BROAD 4.5% [11], BE-

NARROW 3.5% [11], AN 1.5% [13], AN-R 0.8% [13,61], AN-BP 0.7% [13,61]. We assume an additive model, set the p-value significance threshold to 5×10^{-8}, and assessed MAF ranging from 0.01 to 0.5.

Female-only analyses / sex differences

We conducted a supplementary female-only GWAS for BE-BROAD and AN and generated female-only PRS using PRS-CS which we applied on male-only datasets with sufficient data (i.e., *n* case and *n* control >100) available. For the BE-BROAD female-only meta-analysis, all cohorts except *usa1* and *biov* were included, and *alsp, moba,* and *ukd2* were included as male-only target cohorts. For the AN female-only meta-analysis, all cohorts except *itgr*, *spa1, ukd1,* and *net2* were included, and *ipsy, fngn,* and *ukb2* were included as male-only target cohorts.

SNP-based heritability and distinguishing polygenicity from other sources of inflation

We used linkage disequilibrium score regression (LDSC [62]) to estimate SNP-based heritability (h^2_{SNP}). These estimates were transformed to the liability scale, assuming population prevalences as above ("Power Analysis"). For all analyses using LDSC, we applied an LD reference panel based on the European subset of the 1000 Genomes Project (1kGP), restricted to SNPs present in the HapMap3 panel [63]. For *N,* we calculated the sum of effective *N* across all cohorts and specified 0.5 for sample prevalence [64].

Test statistics from GWAS of a polygenic trait are expected to be inflated, but inflation may also be due to spurious SNP associations caused by population stratification and cryptic relatedness of study participants. We used statistics from LDSC [62] to determine the source of inflation. Although the LDSC intercept is commonly used to distinguish polygenicity from spuriously inflated statistics, we calculated the attenuation ratio statistic, defined as (LDSC intercept – 1) / (mean of association chi-square statistics – 1), which may be a useful additional metric [12]. We included variants with MAF ≥ 0.01 and INFO ≥ 0.6.

Comparison of the two binge-eating behaviour phenotypes

The two BE phenotype definitions balanced phenotypic certainty with sample size—BE-BROAD had a larger sample size and was potentially a better-powered GWAS than BE-NARROW, but was likely to be more heterogeneous and could lack specificity to BE. To determine which phenotype to carry forward to follow-up analyses, we considered the LDSC intercept and attenuation ratio statistics and calculated the genetic correlation (SNP-r_g) between the two BE phenotypes. Inflation was a more sizable component of the signal in BE-NARROW (attenuation ratio 0.21 ± 0.06) than in BE-BROAD (0.14 ± 0.04). Furthermore, the SNP-r_g between BE-NARROW and BE-BROAD did not differ from unity (1.00 ± 0.03). We therefore concluded that BE-BROAD appropriately captures the common genetic component of BE with greater statistical power than BE-NARROW.

Genetic relationship between traits

We used LDSC to calculate SNP-r_g with several aims. First, we estimated genetic correlations between AN, AN subtypes, and both BE phenotypes to assess the genetic relationships among these eating disorder traits. Second, we calculated SNP-r_g between AN/BE-BROAD and 225 traits covering eight categories: 1) psychiatric trait or disorder, 2) substance use, 3) psychological/personality/behavioural, 4) anthropometric, 5) metabolism, 6) blood, 7) sociodemographic, and 8) somatic trait or disease. We selected these traits from an internal catalogue based on their power (h^2_{SNP} Z-score > 4) [82]. To assess statistical significance, we applied a Bonferroni-corrected *P*-value threshold of 2.20 x 10^{-4} based on 225 traits. If, according to this threshold, AN and/or BE-BROAD was significantly genetically correlated with another trait, we used the LDSC block-jackknife procedure (described in more detail in Appendix S1 of Hübel et al [83]) to statistically compare the SNP-r_g between AN and BE-BROAD (Bonferroni-corrected *P*-value threshold of 2.20 x 10^{-4}).

To further investigate the genetic difference between BE-BROAD and AN we used CC-GWAS [14]. CC-GWAS uses GWAS summary statistics to test for differences between

cases of two phenotypes, as opposed to a traditional GWAS that tests for differences between cases and controls. We used BE-BROAD and AN summary statistics including non-ambiguous SNPs from HapMap 3 with INFO $\geq$ 0.6 and MAF >= 0.01. We used the liability-scale h^2_{SNP}, the SNP-r_g and associated covariate intercept between both traits as input. We furthermore set the AN population prevalence to 1.5% (range 0.1 - 4.3%) and 7% for BE-BROAD (range 0.1 - 10%), and approximated the number of effective loci to be 10,000–consistent with psychiatric disorder polygenicity [14]. We additionally defined the number of independent CC-GWAS loci with PLINK 1.9 (—clump-p1 5e-8 —clump-p2 5e-8 —clump-r2 0.1 —clump-kb 3000) and defined a genome-wide significant SNP if its *P*-value is < 5 x 10^{-8} in the CC-GWAS OLS test and *P*-value < 10^{-4} in the CC-GWAS exact test. Further, CC-GWAS calculates genetic distances between cases and controls of the two traits using $\sqrt{m \times F_{ST,causal}}$ based on liability-scale h^2_{SNP}, SNP-r_g, population prevalence and the number of independent causal variants of the two traits.

Influence of BMI

We used GWAS-by-subtraction [15], an application of genomicSEM [84], in R v4.3.1 [85] to estimate the proportion of variance in BE-BROAD and AN independent of BMI (Supplementary Methods). Shared genomic covariance across traits is expected due to pleiotropy. Latent genomic structural equation modelling (Genomic SEM) factors explicitly model this covariance, making results less influenced by spurious biases than would conditioning on phenotypic traits in a GWAS [86]. We used GWAS summary statistics from BE-BROAD, AN and BMI [16].

We specified a structural equation model that regressed both sets of summary statistics on a shared variable ("*BMI*") and a non-BMI variable ("*non-BMI*") for each eating disorder trait, respectively (Supplementary Figure 27). Specifically, we specified the two latent variables as a function of BMI and (e.g.) BE-BROAD: "*BMI* =~ *NA* * BEBROAD + start(0.4) * BMI" and *"NonBMI =~ NA* * BE-BROAD". In line with the GWAS-by-subtraction

specification as it has previously been applied [15], we additionally set the variance of the latent variables to 1 and a covariance of 0, and constrained the model so all (co)variance in BMI and BE-BROAD was captured by *BMI* and *NonBMI*. We used the diagonally-weighted least squares estimator, which is the default setting in Genomic SEM [84], and a tolerance of 1 x 10^{-40}. Additional computational settings are shown in Supplementary Table 27. We then regressed the two latent factors on individual SNPs yielding a GWAS of the latent variables *BMI* and *NonBMI*. We subsequently used LDSC [62] to calculate SNP-r_g of the *NonBMI* factor with all traits identified in initial genetic correlations. As a sensitivity analysis, we restricted our BE-BROAD sample in our GWAS to cohorts that were not ascertained for AN, reasoning that this might better capture binge-eating behaviour outside of AN. We applied the same GWAS-by-subtraction model on that selection of cohorts (listed in Supplementary Table 10).

We also conducted exploratory two-sample Mendelian randomisation analyses of BE-BROAD with BMI and AN with BMI, testing causal effects in both directions. We used SNPs in linkage equilibrium as genetic instruments, with P < 5×10^{-6} for BE-BROAD and AN, and P < 5×10^{-9} for BMI [16]. We repeated analyses using the *NonBMI* factor GWAS of BE-BROAD and of AN. To ensure our analyses were robust to potential violations of the assumptions of Mendelian randomisation, we conducted analyses using multiple methods in R 4.3.2, including the packages *TwoSampleMR*, *MendelianRandomisation*, and *MR-PRESSO* (Supplementary Methods) [85,87,88]. These were inverse-variance weighted analysis, MR-Egger, mode-based estimation and median-based estimation. We determined the strength of association of our genetic instruments using the F-statistics [89]. We used Cochran's Q-statistic to test for instrument heterogeneity, with p < 0.05 indicating heterogeneity [90]. To investigate potential confounding via horizontal pleiotropy, we assessed the deviation of the MR-Egger intercept from 0, and performed a global bias test in MR-PRESSO. We excluded from the analysis SNPs identified by MR PRESSO as pleiotropic. We ran further methods robust to heterogeneity, including the penalised weighted median

estimator, the contamination mixture method, and MR-Lasso [91]. We assessed results visually (Supplementary Methods).

Identification of gene-tissue associations with ED phenotypes

We used S-PrediXcan [17] to identify genetically regulated gene expression associated with our phenotypes. We tested the association of gene expression with our ED traits using available GTEx v8 MASHR [17,65,66] and CommonMind DLPFC [67,68] tissue models. MASHR-based PredictDB models use fine-mapping methods for selection of eQTLs included in the predictor models, improving prediction [17,65,66]. We included 45 GTEx v8 MASHR models, removing non-natural tissues (cell lines), tissues with N<100 individuals (kidney cortex), and testis [69]. We performed liftover of our GWAS summary statistics to hg38, harmonisation, and imputation based on recommended preprocessing by Barbeira et. al [65] using *GWAS tools* (see URLs). We established two different Bonferroni significance thresholds: an experiment-wide threshold, where we corrected for 600,382–602,744 tests performed across all tissues ($P < 0.05/\text{Tests}_{Total} = P < 8.32 \times 10^{-8}$), and a tissue-specific threshold, where we corrected for varying numbers of tests performed within each tissue ($P < 0.05/\text{Tests}_{Tissue\,X}$, Supplementary Table 15). We performed two-tailed exact binomial tests for tissue enrichment using *binom.test()* in R for associations at three different significance thresholds: experiment-wide significant ($P < 0.05/\text{Tests}_{Total}$), tissue-specific significant ($P < 0.05/\text{Tests}_{TissueX}$), and nominally significant ($P < 0.05$). We reported results with a focus on central nervous system tissues (brain and cervical spinal cord) and gastrointestinal tissues (oesophagus, colon, stomach, and small intestine).

S-MultiXcan is a summary-level method for measuring the joint association of genetically regulated gene expression across tissues with a phenotype of interest, leveraging shared eQTLs across tissues [70]. Using our GTEx v8 MASHR S-PrediXcan results as input, along with MASHR models, and harmonized, imputed GWAS summary statistics, we ran S-MultiXcan on each of our ED traits for all genes (N=22,241). S-MultiXcan gives as

output the p-value for association of multi-tissue gene expression with the trait of interest (S-MultiXcan P), along with best single-tissue p-value. In order to account for potential false positive associations, we removed any significant S-MultiXcan associations where the single best tissue p-value was greater than 1×10^{-4} [70]. We set a Bonferroni significance threshold for our results, correcting for the number of genes tested in our S-MultiXcan analysis ($P < 0.05/22{,}241 = 2.25 \times 10^{-6}$).

Gene-wise and gene set analysis, including drug target and drug class analyses

Following a previously published approach [71], we used MAGMA v1.10 [18] to test the association between each phenotype and 1) the aggregate effect of SNPs mapped to protein-coding genes (gene analysis); 2) groups of genes with shared functional, biological, or other characteristics (gene-set analysis); 3) a gene-set analysis restricted to genes targeted by drugs (drug-set analysis) and 4) the enrichment of signal within classes of drug. We restricted SNPs to those with MAF >= 0.01, INFO >= 0.6, and which are present in 80% of the total sample and 50% of the cohorts. We mapped SNPs to protein-coding genes, applying a 35 kb upstream and 10 kb downstream window around hg19 gene positions from Ensembl release 75 [72]. We obtained P-values with the multi = snp-wise model, which combines the lowest and mean P-values of all SNPs mapped to the gene. We tested 19,332-19,418 ENSEMBL genes across the five phenotypes and applied a Bonferroni correction of $P < 2.60 \times 10^{-6}$. We used the 1kGP reference panel for estimating between-SNP LD.

For gene-set analyses, we applied a competitive analysis, which regresses the phenotype on the mean effect of genes within the gene set, with the mean effect of genes outside the gene set as a covariate. We defined biological pathways based on gene ontology and canonical pathways from MSigDB v6.1 and psychiatric pathways identified from the literature. We tested 7324-7325 pathways across the five phenotypes and applied a Bonferroni correction of $P < 6.83 \times 10^{-6}$.

For drug-set analyses, we defined drug sets based on drug targets from the Drug-Gene Interaction database DGIdb v4.2.0 [73]; the Psychoactive Drug Screening Database Ki DB [74]; CheMBL v27 [75]; the Target Central Resource Database v6.7.0 [76]; and DSigDB v1.0 [77], all downloaded in October 2020. We applied a competitive analysis and subsequently grouped the results based on the Anatomical Therapeutic Chemical class of the respective drugs [78]. For drug-class analysis, we first ranked all drug-gene sets according to their association in the drug-set analysis. We then generated enrichment curves for specific drug classes, assigning a 'hit' if the drug-gene set belonged to the class or a "miss" if it was outside the class. We calculated the area under the curve and determined statistical significance with the Wilcoxon Mann-Whitney test, comparing drug-gene sets within the class to those outside the class. We applied a Bonferroni correction of $P < 3.23 \times 10^{-5}$ (based on 1546-1547 drug sets) for the drug-set analysis and $P < 3.08 \times 10^{-4}$ (based on 162 drug classes) for the drug-class analysis to account for multiple testing.

Tissue and cell-type specific analyses

To identify relevant tissues and cell-types related to the common genetic risk of BE-BROAD and AN, we performed tissue and cell-type heritability (h^2_{SNP}) enrichment analyses. First, we analysed the enrichment of h^2_{SNP} in 27 tissues from the GTEx gene expression data (v8) after excluding tissues with less than 100 donors, non-natural tissues (such as cell lines), and testis tissues (since it was an expression outlier) [79]. Second, we analysed enrichment of h^2_{SNP} in 31 superclusters and 461 cell clusters based on the single-nucleus RNA sequencing data including over three million nuclei from around 100 dissections across the adult human brain [22]. Within each expression dataset, we calculated the specificity of gene expression per tissue or cell type (superclusters and clusters separately), defined as the expression of each gene (counts per million, CPM) in a tissue or cell type (i.e., the superclusters and clusters respectively) divided by the total expression of this gene across all tissues or cell types in the dataset [80]. We then used the genes with the top 10% specificity

in each tissue or cell type to perform the heritability enrichment analysis using stratified LDSC [80,81]. Specifically, we compared the per-SNP heritability of SNPs within 100kb flankings of the top 10% specific genes and the per-SNP heritability of other SNPs, using the baseline model that adjusted for 53 baseline annotations [81]. We then used the coefficient z-scores to calculate the one-sided p-values. Finally, we accounted for multiple comparisons by calculating FDR per trait for the GTEx dataset (27 tests), the human brain superclusters (31 tests) and clusters (461 tests) respectively.

Polygenic prediction

We used PRS-CS [92] to generate polygenic risk scores (PRS) for BE-BROAD and AN. First, we performed leave-one-cohort-out (LOO) analyses to generate LOO GWAS summary statistics from all cohorts except the target cohort and used this as the base data to calculate individual-level PRS in each target cohort. We included non-ambiguous SNPs with INFO ≥ 0.6 and MAF ≥ 0.01 in the PRS calculation. We used the 1000 Genomes Project Phase 3 EUR reference as the LD reference panel and provided median sample size per LOO meta-analysis as input for PRS-CS. Posterior SNP effect size estimates from PRS-CS were then combined across chromosomes to calculate individual PRS via PLINK (--score 2 4 6 sum) [93]. We standardised the individual PRS by applying the scale function in R (version 4.3.2) [85]. Using the standardised PRS scores, we first assessed the proportion of variance explained by PRS for each phenotype through calculating the nested Nagelkerke's pseudo-R^2 (that is, the pseudo-R^2 of the full model minus that of the model excluding the PRS) [94]. The inclusion of target cohorts for each phenotype was based on the effective sample size (N_{eff} half > 1000), study characteristics, and availability of individual-level data (more detailed information in the Supplementary Methods). Logistic regression was performed for BE-BROAD and AN PRS on BE-BROAD and AN, adjusting for cohort-specific PCs. We then converted the variance explained by each PRS (R^2) to the liability scale using population prevalences of BE-BROAD and AN as used for LDSC [95]. In addition, we divided individuals

into ten PRS decile groups and assessed their relative risk of BE-BROAD and AN compared to the group of individuals in the lowest PRS decile. We also examined predictive performance of each PRS regarding their sensitivity, specificity, and precision to predict BE-BROAD and AN status using the pROC [96] and pracma [97] packages in R by comparing the area under the curve (AUC) of the receiver operating characteristic (ROC) curve and the precision recall (PR) curve of the full model including PRS and PCs as predictors against the null model including PCs only as predictors.

We used female-only GWAS summary statistics as base data in PRS-CS [92] to assess whether female BE-BROAD PRS could be applied to male individuals to assess their BE-BROAD risk in three cohorts (*alsp, moba, ukd2*, $N_{case\_male\_total}$=1,055, $N_{control\_male\_total}$=38,046). The same analysis was performed to examine the association of female AN PRS with male AN risk in three cohorts (*ukb2, fngn, ipsy*, $N_{case\_male\_total}$=1,524, $N_{control\_male\_total}$=388,891).

We assessed whether the levels of BE-BROAD and AN PRS differed across subgroups, including a) those with BE-BROAD only, b) those with both BE-BROAD and AN, and c) those with AN only. Target cohorts for this analysis included cohorts with sufficient data available on some/all subgroups (Supplementary Methods, Supplementary Table 1). Specifically, we selected *aunz* and *sedk* to assess individuals with both BE-BROAD and AN and to assess the AN only group. We selected *ukb2* and *ukd2* for assessing BE-BROAD and AN PRS levels in all subgroups. We assessed differences between subgroups and controls by performing linear regression on each PRS for each subgroup compared to controls, adjusting for cohort-specific genetic PCs. In addition to setting controls as the reference group, we also set different subgroups as the reference group to compare differences in BE-BROAD PRS and AN PRS across different subgroups.

Last, we generated AN PRS from the main meta-analysis – including solely individuals of European genetic ancestry – and applied this to two East Asian cohorts (N_{case}=77, $N_{control}$=117 in a Japanese cohort, N_{case}=75, $N_{control}$=109 in a Korean cohort). Korean data were merged with Japanese data from GCAN cohorts. The same pre-

imputation quality control and imputation method used for the European cohorts was conducted. High quality data for imputation were available for 75 AN cases and 109 controls from the Korean cohort and 77 AN cases and 117 controls from the Japanese cohort. We used the 1000 Genomes Project Phase 3 EUR reference as the LD reference panel for PRS, as the reference panel should align with the ancestry in the base GWAS [92]. We used the European AN prevalence estimate for liability scale conversion, as estimates of AN prevalence in East Asia are sparse and what estimates exist are approximately consistent with estimates in countries with primarily European genetic ancestries [98].

Sensitivity analyses using down-sampled BE-BROAD data

A considerable portion (13%) of the cases for the BE-BROAD GWAS includes individuals who were recruited through studies that focussed on AN ascertainment. Even though the BE-BROAD phenotype is expected to be heterogeneous given its transdiagnostic nature, we sought to understand the influence of AN on this BE-BROAD phenotype. We therefore conducted an additional BE-BROAD meta-analysis where we excluded individuals with BE-BROAD who were identified in cohorts that were specifically ascertained for AN (e.g., the ANGI cohorts). This resulted in an additional analysis including 87% of the BE-BROAD GWAS, consisting of the following cohorts: *sebe, agds, alsp, biov, esbb, fngn, jans, moba, ukb2, ukd2*). We then calculated SNP-r_g to compare the genetic relationship of the "non-AN-ascertained" BE-BROAD GWAS and the original BE-BROAD GWAS with selected traits significantly correlated with the original BE-BROAD GWAS or with the AN GWAS (hypothesising that AN-related effects may mask or drive genetic correlations between such traits and the original BE-BROAD GWAS).

URLS

TopMED Hg37 VCF: https://ftp.ensembl.org/pub/grch37/release-113/data_files/homo_sapiens/GRCh37/variation_genotype/TOPMED_GRCh37.vcf.gz

TopMED Hg38 VCF: https://ftp.ensembl.org/pub/grch37/release-113/data_files/homo_sapiens/GRCh38/variation_genotype/TOPMED_GRCh38.vcf.gz

LiftOver: https://ftp.ensembl.org/pub/grch37/release-113/data_files/homo_sapiens/GRCh38/variation_genotype/TOPMED_GRCh38.vcf.gz

SPrediXcan best practice: https://github.com/hakyimlab/MetaXcan/wiki/Best-practices-for-integrating-GWAS-and-GTEX-v8-transcriptome-prediction-models

GWAS tools:

https://github.com/hakyimlab/summary-gwas-imputation/wiki/GWAS-Harmonization-And-Imputation